

Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for photodynamic therapy of actinic keratoses

Jan-Dirk Fauteck · Günther Ackermann ·
Manfred Birkel · Marion Breuer · Anne C. E. Moor ·
Andrea Ebeling · Christoph Ortland

Received: 29 May 2007 / Revised: 29 June 2007 / Accepted: 21 August 2007 / Published online: 25 October 2007
© Springer-Verlag 2007

Abstract Actinic keratosis (AK) can be treated by photodynamic therapy (PDT), which is becoming a well-established tool in dermatology. Normally a precursor of the photosensitiser is applied topically and converted into protoporphyrin IX (PPIX) in the cells. By activating PPIX with light, the dysplastic cells will be destroyed. We report the results of two clinical studies investigating the properties of a novel self-adhesive 5-ALA-patch (PD P 506 A) intended for PDT of mild to moderate AK on the face and head. The studies investigated the influence of patch application duration on PPIX-specific fluorescence and the pharmacokinetic properties of the 5-ALA patch. The PPIX fluorescence in AK lesions and normal skin after patch application (intraindividual comparison; application for 2, 3, 4, 5 h) was investigated in 13 patients using DYADERM Professional (Biocam). In the subsequent pharmacokinetic study 12 patients were treated with 8 patches each (4 h application). 5-ALA and PPIX were analysed in plasma (over 24 h) and urine (over 12 h). PPIX-specific fluorescence measured immediately after patch removal increased with increasing

application duration to a maximum at 4-h application. The fluorescence in AK lesions was more intense than in normal skin. A small increase of 5-ALA plasma concentrations was observed in 10 of 12 patients after applying 8 patches for 4 h, which rapidly declined to normal values after patch removal. The maximum increase was 3.7-fold of the pre-dose 5-ALA plasma concentration. No PPIX-concentrations above the lower limit of quantification were observed. PPIX-specific fluorescence in AK lesions can be steered by application duration of this novel 5-ALA patch. Application is safe and well tolerable. The observed small rise in 5-ALA plasma concentrations is regarded clinically irrelevant. Clinical efficacy of the patch in PDT will be investigated in further clinical trials.

Keywords Aminolevulinic acid · Fluorescence · Pharmacokinetics · PPIX

Introduction

Actinic keratosis (AK) mainly occurs in people with fair skin. Today, AK is considered as in situ carcinoma, which usually is caused by sun exposure. The head, hands and lower legs, are primarily affected. It is standard of care to treat AK when diagnosed which can be achieved by either physical ablation, chemotherapeutic agents or photodynamic therapy (PDT). For PDT in dermatology, the most frequently used substances are 5-ALA (5-aminolevulinic acid) and its derivative methyl aminolevulinic acid. Studies have proven the effectiveness of topical 5-ALA-PDT in the treatment of actinic keratoses and other superficial skin tumours [3, 8, 14, 15, 18, 19, 25].

The procedure for PDT of AK normally involves the application of 5-ALA or its ester in a dermatological preparation

J.-D. Fauteck · M. Breuer
PROVERUM GmbH, Münsterstraße 111,
48155 Münster, Germany

G. Ackermann
Biocam GmbH, Friedenstraße 30, 93053 Regensburg, Germany

M. Birkel
CRS Clinical Research Services Mannheim GmbH,
Richard-Wagner-Str. 20, 67269 Grünstadt, Germany

A. C. E. Moor · A. Ebeling · C. Ortland (✉)
photonamic GmbH & Co. KG,
Theaterstraße 6, 22880 Wedel, Germany
e-mail: c.ortland@photonamic.de

(e.g. alcoholic solution or cream) for several hours. After application the lesion has to be occluded and protected from light for the whole application period. 5-ALA penetrates the skin and is metabolised to protoporphyrin IX (PPIX). PPIX concentrations resulting from 5-ALA application are higher in tumour cells than in normal cells [10]. PPIX is the actual photosensitiser and will, when excited by light of an appropriate wavelength, lead to the generation of singlet oxygen, which will damage tumour cells and finally lead to cell death [4].

In the clinical studies presented here we tested a newly developed self-adhesive thin 5-ALA patch (PD P 506 A), which has the capability to bypass current handling disadvantages in PDT procedures due to its easy use. The patch has the advantage to deliver 5-ALA to the lesion and protect the newly formed PPIX from bleaching at the same time [16]. The primary aim of the fluorescence analysis study (study code AK 01) was the assessment of the influence of application duration of PD P 506 A on the PPIX specific fluorescence in AK lesions. The second study (study code AK 05) aimed at evaluating the pharmacokinetic parameters of 5-ALA and PPIX when applying eight 5-ALA patches simultaneously to AK lesions for 4 h.

Methods

Both studies were performed as prospective open monocentre study. The fluorescence analysis study (FA study) was designed as intra-individual comparison of different application times of the study patch. The FA study was clinically conducted from February 2004 to April 2004 and the pharmacokinetic study (PK study), from April 2005 to June 2005. The study centre, which was the same for both studies (PROVERUM), is located in Münster, Germany. PROVERUM holds a department, which specialises on the conduct of clinical phase I studies in dermatology. Dermatologists from the surrounding areas send suitable patients to the study centre.

Ethics

Both study protocols and associated information had been submitted to and approved by the Independent Ethics Committee responsible for the principal investigator prior to the starting of the study. The investigations were carried out in accordance with the German Drug Law, national and international GCP-Guidelines and the Declaration of Helsinki.

Study medication

PD P 506 A is a rectangular, skin coloured, self-adhesive patch with rounded corners. One patch contains 2 mg

5-aminolevulinic acid (present as 5-aminolevulinic acid hydrochloride) per cm² and has a size of 4 cm². Four patches, all on a single removable protective film, are packed in a heat-sealed pouch. The pouch provides protection against moisture, light and environmental contamination.

Study population

The aim of each study was to involve 12 patients with mild to moderate AK on the head or face. The following is a list of the most important inclusion and exclusion criteria. Females of childbearing potential were not eligible for the studies. Known or suspect, acute or chronic-hepatic diseases or renal dysfunction led to exclusion of the patients. Patients with dermatologic conditions jeopardising the aim of the study (e.g. scalp psoriasis) were excluded. Any treatment being able to influence the disease status of AK was not permitted 4 weeks prior to or during the study, urea and salicylic-acid containing formulations, 2 weeks prior to or during the study. Patients suitable for the PK study had furthermore to be in good condition with pulse and blood pressure reading within the normal ranges. The patient's alcohol and caffeine consumption characteristics were defined by the study protocol. Post organ transplantation condition, any major concomitant disease or any indication of drug abuse disqualified the patients. In both studies, the studied AK lesions had to be either of mild (defined as flat, pink maculae or patches on sun-damaged skin, background mottling, no roughness or hyperkeratosis) or moderate grade (defined as pink to red papules or plaques with rough, hyperkeratotic surface, variable induration) [5]. The identification of suitable AK lesions and the classification of their severity were done on clinical grounds.

Fluorescence analysis (FA) study

The primary aim of the study was the assessment of the influence of patch application duration (2, 3, 4 or 5 h) on the PPIX-specific fluorescence in AK. The primary parameter was the fluorescence of the patched areas determined directly after patch removal.

In the FA study, four distinct AK study lesions were chosen per patient. The application times of the 5-ALA patch (2, 3, 4, 5 h) were randomly allocated to the lesions. Two lesions of non-affected skin were patched (2, 5 h). No preparation of the study lesions prior to patch application as e.g. curettage was performed. The fluorescence data of all studied areas were referenced to baseline data (background fluorescence prior to patch application). PPIX-specific fluorescence of the study areas was determined at given intervals for all selected skin areas (directly after removal (0 h)

and 2, 4, 6, 24 and 48 h after removal of the 5-ALA patch). In the time between the measurements, all study lesions were protected from ambient light by cotton wool and aluminium foil to prevent fluorescence bleaching. A fluorescent foil was used as fluorescence standard.

Fluorescence measurements were performed with DYADERM, a highly sensitive digital fluorescence imaging system (Biocam GmbH, Regensburg, Germany). DYADERM is a diagnostic medical product for fluorescence diagnostics and serves the early diagnosis of dermal changes [1]. The light source emits light in the range of 370–440 nm. A picture of the fluorescence is taken by an integrated CCD camera and stored electronically. The fluorescence data were analysed by a person blinded to the application duration. After correction of shading and determination of the reference value the fluorescence was determined for the AK area, where the study medication was applied.

Pharmacokinetic (PK) study

The primary aim of the study was the evaluation of the pharmacokinetics of 5-ALA after application of 8 patches for 4 h to mild to moderate AK lesions. The primary parameters were $AUC_{0-\infty}$, AUC_{0-4} , C_{max} , t_{max} , $A_{e,ur}$ and urinary recovery for 5-ALA. Secondary aims of the study were the evaluation of the pharmacokinetics of PPIX and safety of the patch application.

In this study, eight AK lesions of each patient were patched with PD P 506 A for 4 h. The application duration of 4 h had been determined on the basis of the results of the FA study. Again, no curettage of the study lesions was performed prior to patch application. For the determination of the PK parameters, blood and urine samples were collected prior to and during 12 h after start of the patch application. Body weight, body temperature, pulse and blood pressure were measured prior to administration, pulse and blood pressure also at 2, 4 and 8 h after administration. A final blood sample was taken 24 h after the application of the study medication.

For the analysis of 5-ALA in human plasma and human urine and for the analysis of PPIX in human plasma, a chromatographic method (HPLC/fluorescence method) developed and validated by CRS-Mannheim GmbH (Grünstadt, Germany) was used [23]. The bioanalytical procedures of the laboratories were GLP-certified. 5-ALA was determined in plasma by derivatisation with acetylacetone/formaldehyde and separation by high-performance liquid chromatography. The limit of quantification was 11.69 µg/l for 5-ALA. PPIX was isolated from plasma by acidic protein precipitation followed by high performance liquid chromatography with fluorescence detection. The limit of quantification was 4.47 µg/l for PPIX.

Statistical analysis

FA study

The influence of the application duration of the 5-ALA patch on the PPIX fluorescence was statistically evaluated by regarding the observed value of fluorescence directly after patch removal (F_{0h}). The log-transformed fluorescence characteristic F_{0h} was submitted to analysis of variance including the effects of patient and application (four levels with regard to the AK areas) in the model. In order to assess the influence of application duration in a confirmative manner, the multiple test procedure REGWQ was applied. Point estimates with 95% confidence intervals were calculated for the following pair-wise differences of application duration: “3 h minus 2 h”, “4 h minus 2 h”, “5 h minus 2 h”, “4 h minus 3 h”, “5 h minus 3 h” and “5 h minus 4 h”. An additional analysis was run in an exploratory manner by extending the above-mentioned ANOVA to six treatments levels, i.e. the results obtained for normal skin were incorporated.

PK study

All patients having an evaluable treatment period were included in the PK analysis. Calculation of the pharmacokinetic characteristics was based on actual blood-sampling time [h] (relative to the corresponding administration time) rounded to two decimal digits and negative pre-dose times set to zero. Descriptive statistics of concentrations were calculated if at least half of the individual data were quantifiable, concentrations below the LLOQ were calculated as half of the LLOQ. For calculation of the pharmacokinetic characteristics the following rules were applied: At time points in the lag-time between time zero and the first concentration equal or above LLOQ, concentrations below LLOQ were calculated as zero. Concentrations below LLOQ between two quantifiable concentrations were calculated with half the LLOQ. Trailing concentrations below LLOQ were not used in calculations. The 5-ALA plasma concentrations were corrected for pre-dose concentrations ($C_t - C_0$, in the case of $C_0 < \text{LLOQ}$ C_0 was replaced by LLOQ). The primary model-independent pharmacokinetic characteristics for 5-ALA in plasma were calculated using non-compartmental procedures.

Furthermore, a subgroup with an absorption of 5-ALA with C_{max} concentrations $> 1.5 \cdot C_0$ was evaluated statistically in addition to the evaluation of the 5-ALA plasma pharmacokinetics of all 12 patients.

Safety and tolerability

In both studies adverse events were documented. The investigator judged their relation to the study medication.

Local phototoxic reactions were prevented by applying a cover to the study lesions for the 48–72 h after removal of the 5-ALA-patch.

Results

The patient population as well as the selected study lesions shows comparable characteristics for both studies (Tables 1, 2). The majority of study lesions were located on the scalp and forehead. Most of the study lesions (70%) were of mild intensity.

Fluorescence analysis study (FA study)

Thirteen patients were recruited into the study. PPIX fluorescence data are based on the analysis of 48 AK study lesions and 24 normal skin areas (12 patients) which had been patched with the 5-ALA patch as specified in the study protocol and which provided valid fluorescence data. The patient who did not show valid fluorescence data was identified being a “PDT non-responder” retrospectively. All 13 patients were valid for safety evaluation.

Table 1 Summary of patient characteristics of the safety samples of both studies

	FA study <i>N</i> = 13 (safety sample)	PK study <i>N</i> = 12 (safety sample)
Age (years)		
Mean ± SD	69.6 ± 9.87	69.8 ± 7.78
Median (range)	73 (49–80)	71 (50–81)
Sex		
Female	2 (15%)	2 (17%)
Male	11 (85%)	10 (83%)

FA Fluorescence Analysis; PK pharmacokinetic; SD Standard deviation

Table 2 Summary of lesion characteristics of the safety samples of both studies

	Application duration (h)	FA study <i>N</i> = 13 (52 lesions)				PK study <i>N</i> = 12 (96 lesions)
		2 h	3 h	4 h	5 h	4 h
Site						
Scalp		5 (38%)	6 (46%)	4 (31%)	6 (46%)	7 (7%)
Forehead		6 (46%)	4 (31%)	9 (69%)	5 (38%)	68 (71%)
Cheek		2 (15%)	3 (23%)	0	1 (7%)	19 (20%)
Ear		0	0	0	1 (7%)	1 (1%)
Temple		0	0	0	0	1 (1%)
Severity						
Mild		10 (77%)	8 (62%)	11 (85%)	9 (69%)	66 (69%)
Moderate		3 (23%)	5 (38%)	2 (15%)	4 (31%)	30 (31%)

FA Fluorescence Analysis;
PK pharmacokinetic;
SD Standard deviation

Table 3 FA Study: fluorescence at the moment of patch removal (F_{0h} ; *N* = 12) and summary statistics for primary variable

Study area	Application duration (h)	Fluorescence mean (SD)	Fluorescence median (range)
AK lesions	2	1.558 (0.403)	1.635 (0.81–2.17)
	3	2.496 (0.856)	2.580 (0.69–3.76)
	4	3.183 (1.041)	3.220 (1.55–4.95)
	5	3.407 (0.980)	3.260 (1.42–4.79)
Normal skin	2	0.823 (0.157)	0.805 (0.56–1.15)
	5	1.598 (0.649)	1.430 (0.75–2.77)

Baseline fluorescence was well comparable between study lesions. Mean values ranged from 0.66 to 0.70 for all except one AK lesions as well as normal skin areas.


The analysis of variance and multiple test procedure for treatment comparisons yielded the following results for the PPIX fluorescence in AK lesions (Tables 3, 4):

- The 2 h-duration is significantly different from each of the 3, 4 and 5-h durations
- The 3-h duration is significantly different from each of the 4 and 5-h durations
- The 4 and 5-h durations do not show a statistically significant difference.

By applying a repeated measurement model of analysis of variance, a statistically significant interaction between application duration and time was detected. Differences in mean fluorescence levels between the application durations changed over time. The mean profiles for fluorescence data are presented in Fig. 1a. Figure 1b presents the data in reference to the start of patch application. Since there is no difference in the fluorescence profiles depicted from start of the application for the application durations 3, 4 and 5 h, it can be postulated that a saturation of the biological system responsible for the conversion of 5-ALA to PPIX takes place.

Table 4 FA Study: fluorescence at the moment of patch removal (F_{0h} ; $N = 12$): comparison of application durations

Comparison of AK study areas (application duration)	<i>p</i> value
3–2 h	0.0005
4–2 h	<0.0001
5–2 h	<0.0001
4–3 h	0.0200
5–3 h	0.0036
5–4 h	0.4932

**Fig. 1** FA study. **a** Mean profiles for PPIX fluorescence values. **b** Fluorescence values referenced to start of patch application. *Dotted lines*: 3, 4, 5 h application on AK lesions; *solid line*: 2 h application on AK lesions; *dashed line*: 2, 5 h application on normal skin (Normal skin 2 h: *open triangle*; normal skin 5 h: *open square*; AK lesion 2 h: *closed triangle*; AK lesion 3 h: *closed rhomb*; AK lesion 4 h: *closed circle*; AK lesion 5 h: *closed square*)

The fluorescence ratio between AK lesions and normal skin at the time of patch removal is about 2:1 for the 2- and 5-h applications. Exploratory statistical analyses for the comparison of the two application durations 2 and 5 h, on normal skin, provided significant differences at each of the time-points after patch removal besides the 48-h value which was not statistically significantly different ($p = 0.36$). Fluorescence values on AK lesions, 48 h after patch removal, still significantly exceeded the baseline value for all application durations ($p < 0.001$) showing at least 3-fold mean differences between 48 h and baseline (Fig. 1a).

Pharmacokinetic study (PK study)

In the PK study, none of the 144 blood samples (pre-dose samples excluded) deviated from the planned schedule by more than 10 min. The actual blood-sampling times were used for calculations. There were no missing concentration-time data for 5-ALA and PPIX.

5-ALA plasma concentrations increased from endogenous 11.23 $\mu\text{g/l}$ (measured pre-dose) to a maximum of 27.57 $\mu\text{g/l}$ (geometric means of 12 patients; values not baseline corrected). A t_{max} of 3.99 h after start of the application and an AUC_{0-t} of 393.8 $\mu\text{g h/l}$ (median value of 12 patients) were calculated. Descriptive statistics of plasma concentrations of 5-ALA as well as summaries of the results for the pharmacokinetic parameters for 5-ALA (with and without baseline correction) are given in Tables 5, 6, 7. The primary parameter $\text{AUC}_{(0-\infty)}$ could not be calculated for non-baseline corrected values due to the endogenous 5-ALA concentrations mimicking a longer elimination half-life. Figure 2 presents the synoptic plots of the geometric mean concentration-time profiles of 5-ALA plasma concentrations and individual profiles.

Table 5 PK Study: descriptive statistics of 5-ALA plasma concentrations ($\mu\text{g/l}$) ($N = 12$)

Nominal time after application (h)	Geometric mean (SD)	Median (range)
0.00	11.23 (1.49)	13.75 (<LLOQ–15.42)
0.25	14.22 (1.10)	14.26 (12.04–16.49)
0.50	14.06 (1.36)	15.06 (<LLOQ–20.11)
0.75	15.99 (1.14)	15.86 (12.86–20.92)
1.00	16.37 (1.44)	16.81 (<LLOQ–27.95)
1.50	18.59 (1.31)	17.20 (12.94–32.67)
2.00	21.65 (1.38)	21.47 (12.77–37.63)
3.00	25.16 (1.46)	22.22 (15.29–50.69)
4.00	27.57 (1.47)	24.87 (16.98–53.08)
6.00	19.75 (1.31)	20.31 (13.56–31.96)
8.00	16.83 (1.24)	17.44 (12.34–23.48)
12.00	14.81 (1.39)	15.65 (<LLOQ–20.98)
24.00	11.93 (1.60)	13.72 (<LLOQ–25.10)

Table 6 PK study: descriptive characteristics of pharmacokinetic parameters for 5-ALA ($N = 12$)

Parameter	Geometric mean (SD)	Median (range)
C_{max} ($\mu\text{g/l}$)	28.36 (1.44)	25.64 (18.05–53.08)
$\text{AUC}_{(0-t)}$ ($\mu\text{g}^*\text{h/l}$)	350.00 (1.60)	393.81 (109.37–565.64)
T_{max} (h)	4.58 (1.73)	3.99 (3.00–23.97)

Table 7 PK study: descriptive characteristics of baseline corrected pharmacokinetic parameters for 5-ALA ($N = 12$)

Parameter	Geometric mean (SD)	Median
$C_{\max}$ ($\mu\text{g/l}$)	16.45 (2.02)	19.92 (3.57–39.42)
$\text{AUC}_{(0-t)}$ ($\mu\text{g}\cdot\text{h/l}$)	101.37 (2.56)	120.13 (11.53–377.19)
$T_{\max}$ (h)	4.58 (1.73)	3.99 (3.00–23.97)

5-ALA $C_{\max}$ concentrations of 10 of the 12 patients exceeded $1.5 \times \text{baseline}$ (C_0). The maximum increase in 5-ALA plasma concentrations was 3.7-fold of the pre-dose concentration ($C_{\max}$ 53.08 $\mu\text{g/l}$ in one patient). The excretion of 5-ALA in urine in the first 12 h after application was low with a maximum of 2.06% of the dose administered and a median of 1.39%.

For PPIX all analysis results were below the lower limit of quantification (4.470 $\mu\text{g/l}$).

Safety and tolerability

In both studies, the 5-ALA patch PD P 506 A proved to be a safe medication. None of the patients of the FA study experienced any adverse event, which was rated as being causally related to the study medication. Local reactions at


the application site (erythema and pruritus), which were observed in three patients, most probably have their origin in the application of the protection against PPIX bleaching. In the PK study, 7 of 12 patients experienced adverse events. These were reactions at the application site of the study medication (6 patients) and glucose in urine (2 patients). All adverse events were described as mild to moderate. Four patients experienced adverse events at the application site, which were rated by the investigator as being related to the study medication (erythema, irritation and/or pruritus). They all started during (3 patients) or after application (2 patients) of the 5-ALA patch. None of the events in both studies required any intervention.

No serious adverse events were observed. Transaminases and γGT levels were monitored in all patients. In none of the patients a change in liver enzymes was observed when comparing pre- and post-dose values. No clinically significant changes in vital signs or physical findings were reported.

Discussion

PD P 506 A, a self-adhesive 5-ALA patch, was invented to facilitate the application of the photosensitiser's precursor

Fig. 2 **a** Geometric mean ($N = 12$) concentrations of 5-ALA ($\mu\text{g/l}$) versus time (h) following topical administration of 5-ALA patch. **b** All individual ($N = 12$) concentrations of 5-ALA ($\mu\text{g/l}$) versus time (h)



in PDT. The application and subsequent occlusion of e.g. a cream is not only time-consuming for dermatologists and staff but also cosmetically disturbing for the patient. Prior to the start of clinical efficacy studies where the application of the 5-ALA patch would be followed by illumination with light of an appropriate wavelength the basic clinical properties of the 5-ALA patch should be investigated. Two studies were performed: one study had the aim to investigate the influence of the application duration on the PPIX specific fluorescence in AK lesions, the underlying question being whether dosing can be achieved via application duration. After having identified the maximum reasonable application duration for clinical efficacy trials this application duration was investigated for pharmacokinetic characteristics of the patch in the PK study.

Fritsch et al. [11] had shown that fluorescence after application of 5-ALA could be quantitatively linked to PPIX contents in tissue biopsies. A basic assumption of the FA study therefore, was that the fluorescence would reflect the PPIX contents in the studied lesions. In fact, levels of PPIX fluorescence and therefore dosing of 5-ALA can be achieved via variation of duration of patch application. The results furthermore support the previously reported notion that PPIX production is specifically increased in tumour cells as opposed to normal cells [2, 11, 26]. Furthermore, it was shown that the DYADERM system is capable in differentiating between the tested treatments and thus proves to be a sensible method for fluorescence diagnosis.

PPIX generation does not stop when the 5-ALA patch is removed but a 5-ALA deposit in skin might have formed which is subsequently converted to PPIX. However, after 3 h of patch application the biological system, which converts 5-ALA into PPIX, is saturated. Fluorescence increases after this time-point primarily because of the conversion of 5-ALA into PPIX, and probably not because of additional 5-ALA supply (Fig. 1).

The PPIX fluorescence levels after 48 h do not necessarily reflect the clinical setting of PDT. Illumination would take place immediately after patch removal leading to the desired phototoxic effect and cell destruction as well as photo-induced destruction of the photosensitiser (photobleaching) [17]. Some residual 5-ALA in the skin, however, will most probably be available for conversion into PPIX after the end of illumination and can theoretically increase the local phototoxic reaction. It therefore seems reasonable to instruct the patients to protect the treated lesion from light after PDT.

So far, no direct quantitative link between fluorescence intensity and clinical efficacy has been published. Fink-Puches and colleagues observed a strong and statistically significant correlation between “moderate” to “very strong” fluorescence and lesion clearance [8]. Since there was no significant increase of fluorescence between the 4- and 5-h

applications at the time of patch removal, 4 h was chosen as application duration for the PK study and will be the maximum application in clinical efficacy studies.

Studies on the absorption of 5-ALA after topical application using different formulations in different indications have been described in literature. Results vary between studies and strongly depend on formulation and indication. In a study by Rick et al. [22], 5-ALA plasma concentrations did not exceed the detection limit of 0.1 mg/l after topical administration (10% 5-ALA in cream, 6 h incubation). Fritsch et al. did not find a significant increase in 5-ALA and total porphyrin levels in erythrocytes and plasma of patients with AK and basal cell carcinoma (BCC) after topical administration of 5-ALA in total doses varying between 0.02 and 7.0 g [9]. In patients with AK and BCC, no alteration in 5-ALA and porphobilinogen levels in 24 h urine samples were found after topical administration of 5-ALA [30]. However, spontaneous urine samples collected immediately after topical 5-ALA administration for the treatment of AK showed higher 5-ALA concentrations than control samples in 7 out of 10 patients in another study [25]. Traces of porphyrins were found in urine samples taken directly after 5-ALA-PDT in 3 out of 48 patients with epithelial skin tumours [29]. Since a very sensitive detection method for 5-ALA in plasma was used in the present study the results are interpreted as being consistent with published data.

The patient population of PK studies often consists of healthy volunteers. We decided to investigate the PK properties of the 5-ALA patch on damaged skin. Damaged skin facilitates the penetration of externally applied molecules due to its lower barrier [20, 27] and as was shown in the FA study the conversion of 5-ALA to PPIX is faster in AK lesions than in normal skin. A patient study therefore was considered superior to a study in healthy volunteers.

The observed increase in 5-ALA plasma concentrations is considered low in comparison to 5-ALA plasma concentrations recorded after exogenous administration 5-ALA [6]. They are much lower than the plasma concentrations, at which side effects have been reported in literature (oral administration of 10–60 mg 5-ALA/kg BW). These side effects include nausea with or without vomiting, haemodynamic alterations (hypotension), generalised skin phototoxicity and abnormalities in liver function [7, 12, 13, 21, 24, 28]. Since the reported side effects are dose-dependent, it is highly unlikely that any of these reactions will occur after dermal application of PD P 506 A.

In the PK study, PPIX levels were below the lower limit of quantification in all cases. This indicates that there is no danger of phototoxic reactions on any part of the body other than on areas treated with the 5-ALA patch.

The good local tolerability of the 5-ALA patch together with the fact that PPIX was not detectable in plasma

samples prove PD P 506 A being a safe medication. Its application results in the generation of PPIX-specific fluorescence in AK lesions with 4 h application resulting in maximum PPIX fluorescence at patch removal. It has been planned to conduct further clinical trials focussing on the efficacy of the 5-ALA patch after different duration of application in combination with illumination.

Acknowledgments We thank Corinna Gronover and Silke Hallerberg from Proverum GmbH for their support in the accurate realisation of the study protocols. We furthermore thank Manfred Wargenau, Ph.D., M.A.R.C.O. GmbH & Co. KG, and Karl-Ernst Siegler, Ph.D., CRS-Mannheim GmbH, for statistical support. The studies were funded by photonamic GmbH & Co. KG.

References

- Abels C, Ackermann G (2001) Fluorescence diagnosis. In: Calzavara-Pinton PG, Szeimies R-M, Ortel B (eds) Photodynamic therapy and fluorescence diagnosis in dermatology. Comprehensive series in photosciences, vol 2. Elsevier, Amsterdam
- Bäumler W, Abels C, Szeimies R-M (2003) Fluoreszenzdiagnostik in der Dermatologie. JDDG 7. Band 1:569–580
- Calzavara-Pinton PG (1995) Repetitive photodynamic therapy with topical δ -aminolevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B29:53–57
- Cappugi P, Campolmi P, Mavilia L, Prignano F, Rossi R (2001) Topical 5-aminolevulinic acid and photodynamic therapy in dermatology: a minireview. J Chemother 13(5):494–502
- Cockerell CJ (2000) Histopathology of incipient intraepidermal squamous cell carcinoma (“actinic keratosis”). J Am Acad Dermatol, 42(1 Pt 2):11–17
- Dalton JT, Yates CR, Yin D, Straughn A, Marcus SL, Golub AL, Meyer MC (2002) Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. J Pharmacol Exp Ther 301(2):507–512
- Fan KFM, Hopper C, Speight PM, Buonaccorsi G, MacRobert AJ, Bown SG (1996) Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer 78:1374–1383
- Fink-Puches R, Wolf P, Kerl H (1997) Photodynamic therapy of superficial basal cell carcinoma by instillation of aminolevulinic acid and irradiation with visible light. Arch Dermatol 133:1494–1495
- Fritsch C, Verwohlt B, Bolsen K, Ruzicka T, Goerz G (1996) Influence of topical photodynamic therapy with 5-aminolevulinic acid on porphyrin metabolism. Arch Dermatol Res 288:517–521
- Fritsch C, Lang K, Neuse W, Ruzicka T, Lehmann P (1998) Photodynamic diagnosis and therapy in dermatology. Skin Pharmacol Appl Skin Physiol 11:358–373
- Fritsch C, Homey B, Stahl W, Lehmann P, Ruzicka T, Sies H (1998) Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem Photobiol 68(2):218–221
- Grant WE, Hopper C, MacRobert AJ, Speight PM, Bown SG (1993) Photodynamic therapy of oral cancer: photosensitisation with systemic aminolevulinic acid. Lancet 342:147–148
- Herman MA, Webber J, Fromm D, Kessel D (1998) Hemodynamic effects of 5-aminolevulinic acid in humans. J Photochem Photobiol 43:61–65
- Jeffes EW, McCullough JL, Weinstein GD, Kaplan R, Glazer SD, Taylor JR (2001) Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol 45:96–104
- Karrer S, Szeimies RM, Abels C, Landthaler M (1998) The use of photodynamic therapy for skin cancer. Onkologie 21:20–27
- Lieb S, Szeimies RM, Lee G (2002) Self-adhesive thin films for topical delivery of 5-aminolevulinic acid. E J Pharm Biopharm 53:99–106
- Moan J, Streckyte G, Bagdonas S, Bech O, Berg K (1997) Photobleaching of protoporphyrin IX in cells incubated with 5-aminolevulinic acid. Int J Cancer 70(1):90–97
- Morton CA, Whitehurst C, Moseley H, McColl JH, Moore JV, Mackie RM (1996) Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen’s disease. Br J Dermatol 135:766–771
- Ormrod D, Jarvis B (2000) Topical aminolevulinic acid HCl photodynamic therapy. Am J Clin Dermatol 1(2):133–139
- Popken G, Schultze-Seemann W, Seiler KU, Birkel M, Wetterauer U (2000) Intravesical administration of 5-aminolevulinic acid (5-ALA). Safety and pharmacokinetics of 5-ALA and its metabolite protoporphyrin IX. Eur J Clin Pharmacol 56(3):241–246
- Regula J, MacRobert AJ, Gorchein A, Buonaccorsi GA, Thorpe SM, Spencer GM, Hatfield ARW, Bown SG (1995) Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5-aminolevulinic acid induced protoporphyrin IX—a pilot study. Gut 36:67–75
- Rick K, Sroka R, Stepp H, Kriegmair M, Huber RM, Jacob K, Baumgartner R (1997) Pharmacokinetics of 5-aminolevulinic acid-induced protoporphyrin IX in skin and blood. J Photochem Photobiol 40:313–319
- Sakai T, Morita Y (1996) δ -Aminolevulinic acid in plasma or whole blood as a sensitive indicator of lead effects, and its relation to the other home-related parameters. Int Arch Occup Environ Health 68(2):126–132
- Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93:1003–1013
- Szeimies R-M, Karrer S, Sauerwald A, Landthaler M (1996) Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology 192:246–251
- Szeimies R-M, Landthaler M (2002) Photodynamic therapy and fluorescence diagnosis of skin cancers. Recent Results Cancer Res 160:240–245
- van den Akker JT, Holroyd JA, Vernon DI, Sterenberg HJ, Brown SB (2004) Chronic UVB exposure enhances in vitro percutaneous penetration of 5-aminolevulinic acid in hairless mouse skin. Lasers Surg Med 34(2):141–145
- Webber J, Kessel D, Fromm D (1997) Side effects and photosensitization of human tissues after aminolevulinic acid. J Surg Res 68:31–37
- Wennberg AM, Lindholm LE, Alpsten M, Larkö O (1996) Treatment of superficial basal cell carcinomas using topically applied delta-aminolevulinic acid and a filtered xenon lamp. Arch Dermatol Res 288:561–564
- Wennberg AM, Larkö O, Lönnroth P, Larson G, Krogstad AL (2000) Delta-aminolevulinic acid in superficial basal cell carcinomas and normal skin—a microdialysis and perfusion study. Exp Dermatol 25:317–322



Archives of Dermatological Research

Founded in 1869 as Archiv für Dermatologie und Syphilis

[Journal home](#) > [Volumes and issues](#) > Volume 300, issue 2

Search within journal




Volume 300, issue 2, February 2008

7 articles in this issue


Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for photodynamic therapy of actinic keratoses

Jan-Dirk Fauteck, Günther Ackermann ... Christoph Ortlund
Hot Clinical Study | Published: 25 October 2007 | Article: 53




Relationship between expression of tight junction-related molecules and perturbed epidermal barrier function in UVB-irradiated hairless mice

Takuya Yamamoto, Masumi Kurasawa ... Hiroyuki Sasaki
Original Paper | Published: 07 December 2007 | Pages: 61 - 68




Parthenolide-depleted Feverfew (*Tanacetum parthenium*) protects skin from UV irradiation and external aggression

Katharine Martin, Runa Sur ... Michael Southall
Original Paper | Published: 11 December 2007 | Pages: 69 - 80



Rapid detection of homozygous mutations in congenital recessive ichthyosis

Jennie Lugassy, Hans Christian Hennies ... Eli Sprecher
Original Paper | Published: 22 November 2007 | Pages: 81 - 85




Prevalence and familial risk of ephelides in Han Chinese adolescents

Sen Yang, Sheng-Xin Xu ... Xue-Jun Zhang
Original Paper | Published: 30 October 2007 | Pages: 87 - 90

Programmed cell death 1 genotypes are associated with susceptibility to systemic lupus erythematosus among Chinese

Qian Wang, Dongqing Ye ... Xuejun Zhang



For authors

[Submission guidelines](#)

[Ethics & disclosures](#)

[Fees and funding](#)

[Contact the journal](#)

[Submit manuscript](#)

Explore

[Online first articles](#)

[Volumes and issues](#)

[Sign up for alerts](#)

Advertisement


[Advertisement from Springer Nature](#)

Development of autoantibody responses in NC/Nga mice: its prevention by pulverized konjac glucomannan feeding

Nobukazu Onishi, Seiji Kawamoto ... Kazuhisa Ono

Short Communication | Published: 16 October 2007 |

Pages: 95 - 99



Hot Clinical Study | Published: 25 October 2007

Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for photodynamic therapy of actinic keratoses

Jan-Dirk Fauteck, Günther Ackermann, Manfred Birkel, Marion Breuer, Anne C. E. Moor, Andrea Ebeling & Christoph Ortland *Archives of Dermatological Research* 300, Article number: 53 (2008) | [Cite this article](#)266 Accesses | 20 Citations | [Metrics](#)

Abstract

Actinic keratosis (AK) can be treated by photodynamic therapy (PDT), which is becoming a well-established tool in dermatology. Normally a precursor of the photosensitiser is applied topically and converted into protoporphyrin IX (PPIX) in the cells. By activating PPIX with light, the dysplastic cells will be destroyed. We report the results of two clinical studies investigating the properties of a novel self-adhesive 5-ALA-patch (PD P 506 A) intended for PDT of mild to moderate AK on the face and head. The studies investigated the influence of patch application duration on PPIX-specific fluorescence and the pharmacokinetic properties of the 5-ALA patch. The PPIX fluorescence in AK lesions and normal skin after patch application (intraindividual comparison; application for 2, 3, 4, 5 h) was investigated in 13 patients using DYADERM Professional (Biocam). In the subsequent pharmacokinetic study 12 patients were treated with 8 patches each (4 h application). 5-ALA and PPIX were analysed in plasma (over 24 h) and urine (over 12 h). PPIX-specific fluorescence measured immediately after patch removal increased with increasing application duration to a maximum at 4-h application. The fluorescence in AK lesions was more intense than in normal skin. A small increase of 5-ALA plasma concentrations was observed in 10 of 12 patients after applying 8 patches for 4 h, which rapidly declined to normal values after patch removal. The maximum increase was 3.7-fold of the pre-dose 5-ALA plasma concentration. No PPIX-concentrations above the lower limit of quantification were observed. PPIX-specific fluorescence in AK lesions can be steered by application duration of this novel 5-ALA patch. Application is safe and well tolerable. The observed small rise in 5-ALA plasma concentrations is regarded clinically irrelevant. Clinical efficacy of the patch in PDT will be investigated in further clinical trials.

This is a preview of subscription content, [access via your institution](#).

References

1. Abels C, Ackermann G (2001) Fluorescence diagnosis. In: Calzavara-Pinton PG, Szeimies R-M, Ortel B (eds) Photodynamic therapy and fluorescence diagnosis in dermatology. Comprehensive series in photosciences, vol 2. Elsevier, Amsterdam
2. Bäumler W, Abels C, Szeimies R-M (2003) Fluoreszenzdiagnostik in der Dermatologie. JDDG 7. Band 1:569–580
[Google Scholar](#)
3. Calzavara-Pinton PG (1995) Repetitive photodynamic therapy with topical 5-aminolevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. *J Photochem Photobiol B* 29:53–57
[Google Scholar](#)
4. Cappugi P, Campolmi P, Mavilia L, Prignano F, Rossi R (2001) Topical 5-aminolevulinic acid and photodynamic therapy in dermatology: a minireview. *J Chemother* 13(5):494–502
[PubMed](#) [CAS](#) [Google Scholar](#)

Access options

[Buy article PDF](#)**US\$ 39.95**

Tax calculation will be finalised during checkout.


Instant access to the full article PDF.

[Rent this article via DeepDyve.](#)[Learn more about institutional subscriptions](#)

Sections

[Figures](#)[References](#)[Abstract](#)[References](#)[Acknowledgments](#)[Author information](#)[Rights and permissions](#)[About this article](#)

Advertisement



5. Cockerell CJ (2000) Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). *J Am Acad Dermatol*, 42(1 Pt 2):11–17
[PubMed](#) [Article](#) [CAS](#) [Google Scholar](#)

6. Dalton JT, Yates CR, Yin D, Straughn A, Marcus SL, Golub AL, Meyer MC (2002) Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. *J Pharmacol Exp Ther* 301(2):507–512
[PubMed](#) [Article](#) [CAS](#) [Google Scholar](#)

7. Fan KFM, Hopper C, Speight PM, Buonaccorsi G, MacRobert AJ, Bown SG (1996) Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. *Cancer* 78:1374–1383
[PubMed](#) [Article](#) [CAS](#) [Google Scholar](#)

8. Fink-Puches R, Wolf P, Kerl H (1997) Photodynamic therapy of superficial basal cell carcinoma by instillation of aminolevulinic acid and irradiation with visible light. *Arch Dermatol* 133:1494–1495
[PubMed](#) [Article](#) [CAS](#) [Google Scholar](#)

9. Fritsch C, Verwohlt B, Bolsen K, Ruzicka T, Goerz G (1996) Influence of topical photodynamic therapy with 5-aminolevulinic acid on porphyrin metabolism. *Arch Dermatol Res* 288:517–521
[PubMed](#) [CAS](#) [Google Scholar](#)

10. Fritsch C, Lang K, Neuse W, Ruzicka T, Lehmann P (1998) Photodynamic diagnosis and therapy in dermatology. *Skin Pharmacol Appl Skin Physiol* 11:358–373
[PubMed](#) [Article](#) [CAS](#) [Google Scholar](#)

11. Fritsch C, Homey B, Stahl W, Lehmann P, Ruzicka T, Sies H (1998) Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. *Photochem Photobiol* 68(2):218–221
[PubMed](#) [CAS](#) [Google Scholar](#)

12. Grant WE, Hopper C, MacRobert AJ, Speight PM, Bown SG (1993) Photodynamic therapy of oral cancer: photosensitisation with systemic aminolaevulinic acid. *Lancet* 342:147–148
[PubMed](#) [Article](#) [CAS](#) [Google Scholar](#)

13. Herman MA, Webber J, Fromm D, Kessel D (1998) Hemodynamic effects of 5-aminolevulinic acid in humans. *J Photochem Photobiol* 43:61–65
[Article](#) [CAS](#) [Google Scholar](#)

14. Jeffes EW, McCullough JL, Weinstein GD, Kaplan R, Glazer SD, Taylor JR (2001) Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. *J Am Acad Dermatol* 45:96–104
[PubMed](#) [Article](#) [CAS](#) [Google Scholar](#)

15. Karrer S, Szeimies RM, Abels C, Landthaler M (1998) The use of photodynamic therapy for skin cancer. *Onkologie* 21:20–27
[Article](#) [Google Scholar](#)

16. Lieb S, Szeimies RM, Lee G (2002) Self-adhesive thin films for topical delivery of 5-aminolevulinic acid. *E J Pharm Biopharm* 53:99–106
[Article](#) [CAS](#) [Google Scholar](#)

17. Moan J, Streckyte G, Bagdonas S, Bech O, Berg K (1997) Photobleaching of

protoporphyrin IX in cells incubated with 5-aminolevulinic acid. *Int J Cancer* 70(1):90–97

[PubMed](#) [Article](#) [CAS](#) [Google Scholar](#)

18. Morton CA, Whitehurst C, Moseley H, McColl JH, Moore JV, Mackie RM (1996) Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. *Br J Dermatol* 135:766–771

[PubMed](#) [Article](#) [CAS](#) [Google Scholar](#)

19. Ormrod D, Jarvis B (2000) Topical aminolevulinic acid HCl photodynamic therapy. *Am J Clin Dermatol* 1(2):133–139

[PubMed](#) [Article](#) [CAS](#) [Google Scholar](#)

20. Popken G, Schultze-Seemann W, Seiler KU, Birkel M, Wetterauer U (2000) Intravesical administration of 5-aminolevulinic acid (5-ALA). Safety and pharmacokinetics of 5-ALA and its metabolite protoporphyrin IX. *Eur J Clin Pharmacol* 56(3):241–246

[PubMed](#) [Article](#) [CAS](#) [Google Scholar](#)

21. Regula J, MacRobert AJ, Gorchein A, Buonaccorsi GA, Thorpe SM, Spencer GM, Hatfield ARW, Bown SG (1995) Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5-aminolevulinic acid induced protoporphyrin IX—a pilot study. *Gut* 36:67–75

[PubMed](#) [Article](#) [CAS](#) [Google Scholar](#)

22. Rick K, Sroka R, Stepp H, Kriegmair M, Huber RM, Jacob K, Baumgartner R (1997) Pharmacokinetics of 5-aminolevulinic acid-induced protoporphyrin IX in skin and blood. *J Photochem Photobiol* 40:313–319

[Article](#) [CAS](#) [Google Scholar](#)

23. Sakai T, Morita Y (1996) δ -Aminolevulinic acid in plasma or whole blood as a sensitive indicator of lead effects, and its relation to the other home-related parameters. *Int Arch Occup Environ Health* 68(2):126–132

[PubMed](#) [CAS](#) [Google Scholar](#)

24. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. *J Neurosurg* 93:1003–1013

[PubMed](#) [CAS](#) [Article](#) [Google Scholar](#)

25. Szeimies R-M, Karrer S, Sauerwald A, Landthaler M (1996) Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. *Dermatology* 192:246–251

[PubMed](#) [CAS](#) [Article](#) [Google Scholar](#)

26. Szeimies R-M, Landthaler M (2002) Photodynamic therapy and fluorescence diagnosis of skin cancers. *Recent Results Cancer Res* 160:240–245

[PubMed](#) [Google Scholar](#)

27. van den Akker JT, Holroyd JA, Vernon DI, Sterenborg HJ, Brown SB (2004) Chronic UVB exposure enhances in vitro percutaneous penetration of 5-aminolevulinic acid in hairless mouse skin. *Lasers Surg Med* 34(2):141–145

[PubMed](#) [Article](#) [Google Scholar](#)

28. Webber J, Kessel D, Fromm D (1997) Side effects and photosensitization of human tissues after aminolevulinic acid. *J Surg Res* 68:31–37

[PubMed](#) [Article](#) [CAS](#) [Google Scholar](#)

29. Wennberg AM, Lindholm LE, Alpsten M, Larkö O (1996) Treatment of superficial basal cell carcinomas using topically applied delta-aminolaevulinic acid and a filtered xenon lamp. *Arch Dermatol Res* 288:561-564

[PubMed](#) [CAS](#) [Google Scholar](#)

30. Wennberg AM, Larkö O, Lönnroth P, Larson G, Krogstad AL (2000) Delta-aminolevulinic acid in superficial basal cell carcinomas and normal skin—a microdialysis and perfusion study. *Exp Dermatol* 25:317-322

[Article](#) [CAS](#) [Google Scholar](#)

[Download references](#) ↴

Acknowledgments

We thank Corinna Gronover and Silke Hallerberg from Proverum GmbH for their support in the accurate realisation of the study protocols. We furthermore thank Manfred Wargenau, Ph.D., M.A.R.C.O. GmbH & Co. KG, and Karl-Ernst Siegler, Ph.D., CRS-Mannheim GmbH, for statistical support. The studies were funded by photonamic GmbH & Co. KG.

Author information

Affiliations

PROVERUM GmbH, Münsterstraße 111, 48155, Münster, Germany

Jan-Dirk Fauteck & Marion Breuer

Biocam GmbH, Friedenstraße 30, 93053, Regensburg, Germany

Günther Ackermann

CRS Clinical Research Services Mannheim GmbH, Richard-Wagner-Str. 20, 67269, Grünstadt, Germany

Manfred Birkel

photonamic GmbH & Co. KG, Theaterstraße 6, 22880, Wedel, Germany

Anne C. E. Moor, Andrea Ebeling & Christoph Ortland

Corresponding author

Correspondence to Christoph Ortland.

Rights and permissions

[Reprints and Permissions](#)

About this article

Cite this article

Fauteck, JD., Ackermann, G., Birkel, M. *et al.* Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for photodynamic therapy of actinic keratoses. *Arch Dermatol Res* **300**, 53 (2008). <https://doi.org/10.1007/s00403-007-0787-0>

[Download citation](#) ↴

Received

29 May 2007

Revised

29 June 2007

Accepted

21 August 2007

Published

25 October 2007

DOI

<https://doi.org/10.1007/s00403-007-0787-0>

Keywords

Aminolevulinic acid

Fluorescence

Pharmacokinetics

PPIX